J9150 Daunorubicin Injection — HCPCS Reimbursement

HCPCS Level II code J9150 denotes a 10 mg injection of daunorubicin, an anthracycline chemotherapy agent used in oncologic treatment regimens. Nationally, granular J‑code reporting supports consistent billing and tracking of chemotherapy utilization, cost, and safety monitoring across payers and sites of care. This code matters for providers, payers, and policymakers because it affects drug cost reporting, prior authorization workflows, and site-of-service payment differentials.

Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how J9150 is categorized for billing, typical clinical contexts for its use, and standard sites where the drug is administered. The publication summarizes common modifiers associated with chemotherapy drug billing (listed separately), discusses typical reimbursement considerations, and outlines benchmarks and policy updates relevant to cancer drug administration. It also highlights operational considerations for infusion centers and hospital outpatient departments related to accurate unit reporting and documentation. Data not available in the input is noted where applicable.

Billing Code Overview

HCPCS Level II code J9150 represents an intravenous injection formulation of daunorubicin, 10 mg. This code is used to bill for the administered dose of the anthracycline chemotherapy agent daunorubicin, supplied and injected in 10 mg increments.

Service Type: Chemotherapy drug administration

Typical Site of Service: Oncology outpatient infusion center or hospital outpatient department

Clinical Context

A 62-year-old patient with newly diagnosed acute myeloid leukemia (AML) presents to the oncology infusion center for induction chemotherapy. The treatment plan includes combination anthracycline-based chemotherapy, with intravenous daunorubicin dosed and administered per oncology protocol. The typical clinical workflow begins with a pre-infusion assessment by an oncology nurse and physician: verification of diagnosis and chemotherapy orders, review of baseline labs (CBC with differential, comprehensive metabolic panel), assessment of performance status, informed consent, and confirmation of venous access. Pharmacy compounds the appropriate dose of J9150 (daunorubicin 10 mg per vial) under sterile conditions; the infusion line is primed and antiemetic premedication is given as ordered. During administration, vital signs and infusion site are monitored for extravasation and acute reactions. Post-infusion monitoring includes observation for hypotension, arrhythmia risks, and scheduling of follow-up labs and cardiology evaluation as indicated by cumulative anthracycline exposure. Typical site of service is an outpatient hospital-based infusion center or an oncology clinic infusion suite; inpatient administration may occur for induction requiring intensive monitoring.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier — standard billing	Use when no specific billing modifier applies to the service.

Taxonomy Code	Specialty	Notes
`208000000X`	Medical Oncology	Primary specialty prescribing and overseeing `J9150` administration.
`207RC0000X`	Hematology	Hematologist involved in diagnosis and chemo regimen planning for leukemias.
`363L00000X`	Registered Nurse (Infusion)	Nurses perform pre-infusion assessment, administration, and monitoring.
`207K00000X`	Internal Medicine	Hospitalists or internists may manage inpatient chemotherapy patients and comorbidities.
`208800000X`	Pediatric Hematology-Oncology	Relevant when `J9150` is used in pediatric leukemia protocols.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C92.0`	Acute myeloblastic leukemia with (acute) maturation	A primary indication for daunorubicin as part of induction chemotherapy regimens.
`C92.00`	Acute myeloblastic leukemia, not having achieved remission	Represents active AML where daunorubicin may be used for induction or re-induction.
`C92.01`	Acute myeloblastic leukemia, in remission	May be included in records for consolidation or follow-up context; chemotherapy regimens differ.
`C94.4`	Acute erythroid leukemia	Less common subtype of acute leukemia where anthracyclines like daunorubicin may be part of therapy.
`C95.00`	Acute leukemia of unspecified cell type, not having achieved remission	Used when cell lineage not specified but cytotoxic chemotherapy such as daunorubicin is indicated.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96413`	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug	Commonly billed for the initial IV infusion of daunorubicin when infusion time is up to 1 hour.
`96415`	Chemotherapy administration, intravenous infusion technique; each additional hour (list separately in addition to code for primary infusion)	Billed when daunorubicin infusion or concurrent fluid administration extends beyond the first hour.
`96417`	Chemotherapy administration, intravenous infusion technique; each additional sequential infusion of a new drug (up to 1 hour)	Used when multiple sequential IV chemotherapy drugs are administered during the same encounter.
`96365`	Intravenous infusion, for therapy, pharmacologic, or nutrition; initial, up to 1 hour	Sometimes used for supportive IV therapies (e.g., hydration, antiemetics) given with daunorubicin.
`36415`	Collection of venous blood by venipuncture	Performed before chemotherapy to obtain baseline and monitoring labs.
`92950`	Cardiopulmonary resuscitation (CPR)	Reserved for emergency events during infusion; included for completeness of potential emergent services.

OpenPayer

Summary & Overview

HCPCS J9150: Daunorubicin Injection, 10 mg